Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
gptkb:FDA
1978 |
| gptkbp:ATCCode |
N03AG01
|
| gptkbp:brand |
gptkb:valproic_acid
|
| gptkbp:contraindication |
gptkb:liver_disease
pregnancy |
| gptkbp:discoveredIn |
1960s
|
| gptkbp:drugClass |
anticonvulsant
mood stabilizer |
| gptkbp:eliminationHalfLife |
9-16 hours
|
| gptkbp:form |
capsule
oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Depakene
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AbbVie
|
| gptkbp:mechanismOfAction |
increases GABA levels
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:sideEffect |
nausea
vomiting hair loss pancreatitis weight gain drowsiness liver toxicity teratogenicity |
| gptkbp:usedFor |
bipolar disorder
epilepsy migraine prevention |
| gptkbp:bfsParent |
gptkb:valproic_acid
|
| gptkbp:bfsLayer |
6
|